 |
0 Diseases |  |
4 Trials |
|
4 Trials |  |
82 News |  |
| 12» |
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 13, 2024
P3, N=669, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2024 --> Sep 2025
- | thioguanine / Generic mfg.
Trial completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Jul 22, 2024
P3, N=280, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Sep 2024 --> Sep 2025 Trial completion date: Jun 2024 --> Jul 2025
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 15, 2024
P3, N=218, Completed, Sponsor: Children's Oncology Group
Trial completion date: Jun 2024 --> Jul 2025 Active, not recruiting --> Completed
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 5, 2024
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Xospata (gilteritinib) / Astellas, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Mylotarg (gemtuzumab ozogamicin) / Pfizer
Enrollment closed: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov) - Mar 12, 2024
P3, N=1400, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 18, 2023
P3, N=669, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial completion date: Apr 2024 --> Sep 2024
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion date: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2023
P3, N=218, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Apr 2024 --> Sep 2024 Trial completion date: Jul 2023 --> Jun 2024
- | Kidrolase (L-asparaginase) / Jazz, Merck (MSD), Erwinase (erwinia L-asparaginase) / Jazz, Ohara Pharma, Oncaspar liquid (pegaspargase) / Servier
Journal: Our Experiences with Asparaginase Activity Measurements in Children with Lymphoblastic Diseases. (Pubmed Central) - Jul 29, 2023
Trial completion date: Jul 2023 --> Jun 2024 Monitoring of AEA can help to identify patients with 'silent inactivation' and their asparaginase therapy can thus be optimized.
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 23, 2023
P3, N=669, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Monitoring of AEA can help to identify patients with 'silent inactivation' and their asparaginase therapy can thus be optimized. Trial completion date: Jun 2023 --> Apr 2024
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 25, 2023
P3, N=669, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2023 --> Apr 2024 Trial completion date: Dec 2030 --> Jun 2023
- || Kidrolase (L-asparaginase) / Jazz, Merck (MSD), Spectrila (asparaginase Escherichia coli) / Medac
ALL-T: how do you use Spectrila, same scheme as Kidrolase or less?#spectrila # ALL-T @AaronGoodman33 @smbenlazar @nihardesai7 @melmehdi (Twitter) - Nov 19, 2022
- Kidrolase (L-asparaginase) / Jazz, Merck (MSD)
A Targeted Catalytic Nanobody (T-CAN) with Asparaginolytic Activity (Poster Area) - Jun 28, 2022 - Abstract #EACR2022EACR_542;
The T-CAN fusion protein also retains ASNase activity (4.30±0.26 U/mg), can bind CD19 and show increased cytotoxic activity on CD19 positive B-ALL cell lines compared to the full-length Kidrolase (percentage of live cells at 0.3 U/mL: 21.42±3.60% vs. 35.47±3.40% for REH, respectively, and 76.66±5.10% vs. 89.02±4.51% for RAJI cells). Conclusion sdASNase and T-CAN represent a strong proof-of-concept for further engineering of new, unexplored platforms for the transfer and targeting of ASNase activity and provide the basis for the formulation of ASNase-based drugs with reduced side effects and improved efficacy.
- | thioguanine / Generic mfg.
Trial completion date, Trial primary completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Jun 15, 2022
P3, N=312, Active, not recruiting, Sponsor: Children's Oncology Group
Conclusion sdASNase and T-CAN represent a strong proof-of-concept for further engineering of new, unexplored platforms for the transfer and targeting of ASNase activity and provide the basis for the formulation of ASNase-based drugs with reduced side effects and improved efficacy. Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Sep 2025 --> Jun 2024
- | thioguanine / Generic mfg.
Enrollment closed: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - May 3, 2022
P3, N=312, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Sep 2025 --> Jun 2024 Recruiting --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 22, 2022
P3, N=670, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial completion date: Jun 2022 --> Dec 2030
- | Kidrolase (L-asparaginase) / Jazz, Merck (MSD)
Journal: Ultrahigh-Resolution NMR with Water Signal Suppression for a Deeper Understanding of the Action of Antimetabolic Drugs on Diffuse Large B-Cell Lymphoma. (Pubmed Central) - Apr 5, 2022
The statistical analyses carried out on the resulting metabolic profiles allow us to successfully highlight several metabolic pathways affected by these drugs. Notably, we show that Kidrolase plays a major role in the metabolic pathways of this DLBCL cell line.
- || imatinib / Generic mfg.
Clinical, Journal: ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. (Pubmed Central) - Mar 29, 2022
In this study we investigated the metabolic pathways responsible for CML surviving to imatinib exposure and its potential therapeutic utility to improve the efficacy of TKI against stem-like CML cells...Glutamine metabolism was inhibited by L-asparaginases such as Kidrolase or Erwinase without inducing predominant CML cell death...The combination of TKI with L-asparaginase reactivated the intinsic apoptotic pathway leading to efficient CML cell death. Thus, targeting glutamine metabolism with the clinically-approved drug Kidrolase, in combination with TKI which suppresses glycolysis, represents an effective and widely applicable therapeutic strategy for eradicating CML stem cells.
- | thioguanine / Generic mfg.
Trial primary completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Mar 22, 2022
P3, N=312, Recruiting, Sponsor: Children's Oncology Group
Thus, targeting glutamine metabolism with the clinically-approved drug Kidrolase, in combination with TKI which suppresses glycolysis, represents an effective and widely applicable therapeutic strategy for eradicating CML stem cells. Trial primary completion date: Jun 2023 --> Sep 2025
- | Kidrolase (L-asparaginase) / Jazz, Merck (MSD)
Journal: The Alternative RelB NF-kB Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells. (Pubmed Central) - Feb 26, 2022
RelB also confers DLBCL cell resistance to glutamine deprivation, an essential amino acid that feeds the TCA cycle. Taken together, our findings uncover a new role for RelB in the regulation of DLBCL cell metabolism and DLBCL cell survival upon metabolic stress.
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 2, 2021
P3, N=670, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Taken together, our findings uncover a new role for RelB in the regulation of DLBCL cell metabolism and DLBCL cell survival upon metabolic stress. Trial primary completion date: Dec 2022 --> Jun 2021
- Zarzio (filgrastim biosimilar) / Novartis
[VIRTUAL] THROMBOPHILIA AS RISK FACTOR FOR ASPARAGINASE RELATED VENOUS THROMBOEMBOLISM IN PEDIATRIC AND YOUNG ADULT PATIENTS AFFECTED BY ACUTE LYMPHOBLASTIC LEUKEMIA () - May 13, 2021 - Abstract #EHA2021EHA_800;
The types of drugs used were: the native form derived from E. Coli (Medac® and Kidrolase®); the form derived from Erwinia Chrysanthemi (Erwinase®); and the pegylated E. coli ASP (PEG-ASP -Oncaspar®)...Conclusion Although thrombophilia is a well-known risk factor for VTE in ALL, our study focused on its link with ASP-related VTE. We suggests that screening for thrombophilia should be performed in ALL patients before ASP administration, since thrombophilic ALL patients may benefit from VTE prophylaxis.
- Vanflyta (quizartinib) / Daiichi Sankyo
[VIRTUAL] Antimetabolic Cooperativity with l-Asparaginase and Tyrosine Kinase Inhibitor Quizartinib to Eradicate Persistant FLT3-ITD Leukemic Cells (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_2348;
Conclusion Persistent leukemia cells that survive after exposure to FLT3 inhibitor quizartinib can be targeted by the clinical drug L-asparaginases. This metabolic strategy could reduce the emergence of leukemic cells resistant to quizartinib.
- | Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion date: AAML0531: Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 26, 2020
P3, N=1070, Completed, Sponsor: Children's Oncology Group
This metabolic strategy could reduce the emergence of leukemic cells resistant to quizartinib. Trial completion date: Aug 2013 --> Sep 2020
- | thioguanine / Generic mfg.
Trial primary completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Sep 19, 2020
P3, N=256, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Aug 2013 --> Sep 2020 Trial primary completion date: Mar 2023 --> Jun 2023
- | Xospata (gilteritinib) / Astellas, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion date, Trial primary completion date: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov) - Sep 19, 2020
P3, N=1400, Recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Mar 2023 --> Jun 2023 Trial completion date: Feb 2025 --> Sep 2027 | Trial primary completion date: Feb 2025 --> Sep 2027
- | Xospata (gilteritinib) / Astellas, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Mylotarg (gemtuzumab ozogamicin) / Pfizer
Enrollment open: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov) - Jul 22, 2020
P3, N=1400, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Feb 2025 --> Sep 2027 | Trial primary completion date: Feb 2025 --> Sep 2027 Not yet recruiting --> Recruiting
- | dasatinib / Generic mfg.
Trial completion: AALL0622: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 13, 2020
P2/3, N=63, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Enrollment closed: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 6, 2020
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Active, not recruiting
- | dasatinib / Generic mfg.
Enrollment closed, Trial completion date: AALL0622: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 1, 2020
P2/3, N=63, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Completed --> Active, not recruiting | Trial completion date: Sep 2015 --> Mar 2020
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Enrollment closed: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 24, 2020
P3, N=218, Active, not recruiting, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting | Trial completion date: Sep 2015 --> Mar 2020 Completed --> Active, not recruiting
- | thioguanine / Generic mfg.
Trial primary completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Mar 13, 2020
P3, N=256, Recruiting, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting Trial primary completion date: Mar 2022 --> Mar 2023
- | Xospata (gilteritinib) / Astellas, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Mylotarg (gemtuzumab ozogamicin) / Pfizer
New P3 trial: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov) - Mar 3, 2020
P3, N=1400, Not yet recruiting, Sponsor: Children's Oncology Group
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Trial completion date: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 23, 2019
P3, N=1641, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2022 --> Mar 2023 Completed --> Active, not recruiting | Trial completion date: Mar 2019 --> Sep 2027
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 3, 2019
P3, N=598, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting | Trial completion date: Mar 2019 --> Sep 2027 Recruiting --> Active, not recruiting
- | thioguanine / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Sep 11, 2019
P3, N=205, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion: Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 6, 2019
P3, N=393, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Leunase (L-asparaginase) / Kyowa Kirin, Kidrolase (L-asparaginase) / Jazz, Merck (MSD), Spectrila (asparaginase Escherichia coli) / Medac
Trial completion: AALL07P2: Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 6, 2019
P=N/A, N=59, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Trial completion: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 20, 2019
P3, N=1644, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Kidrolase (L-asparaginase) / Jazz, Merck (MSD), Erwinase (erwinia L-asparaginase) / Jazz, Bioprofarma
Journal: Experimental and bioinformatics study for production of L-asparaginase from Bacillus licheniformis: a promising enzyme for medical application. (Pubmed Central) - Mar 24, 2019
The optimum conditions for maximum L-asparaginase production by the improved mutant were 39.57 °C, 7.39 pH, 20.74 h, 196.40 rpm, 0.5% glucose, 0.1% ammonium chloride, and 10 mM magnesium sulphate. Taken together, Bacillus licheniformis L-asparaginase can be considered as a promising candidate for clinical application as antileukemic agent.
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 13, 2018
P3, N=1750, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Taken together, Bacillus licheniformis L-asparaginase can be considered as a promising candidate for clinical application as antileukemic agent. Trial primary completion date: Dec 2018 --> Mar 2019
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 13, 2018
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2018 --> Mar 2019 Trial primary completion date: Mar 2022 --> Oct 2022
- | thioguanine / Generic mfg.
Trial primary completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Aug 16, 2018
P3, N=256, Recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Mar 2022 --> Oct 2022 Trial primary completion date: Dec 2019 --> Mar 2022
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 14, 2018
P3, N=1750, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2019 --> Mar 2022 Trial primary completion date: Sep 2018 --> Dec 2018
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion, Trial completion date, Trial primary completion date: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 17, 2018
P3, N=218, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Sep 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2017 | Trial primary completion date: Sep 2018 --> Sep 2017
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial completion: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Jun 15, 2018
P3, N=1895, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2017 | Trial primary completion date: Sep 2018 --> Sep 2017 Active, not recruiting --> Completed
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 13, 2017
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Apr 2018 --> Mar 2022
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial primary completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Dec 12, 2017
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2018 --> Mar 2022 Trial primary completion date: Aug 2013 --> Sep 2017
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial primary completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 16, 2017
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2013 --> Sep 2017 Trial primary completion date: Sep 2017 --> Aug 2013
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Enrollment closed: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 9, 2017
P3, N=1750, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2017 --> Aug 2013 Recruiting --> Active, not recruiting
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 17, 2017
P3, N=1750, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Sep 2018